Congestion

New York City greenlights congestion pricing – here’s how this toll plan is expected to improve traffic, air quality and public transit

Retrieved on: 
Wednesday, April 10, 2024

New York City is poised to launch the first congestion pricing plan to reduce traffic in a major U.S. metropolitan area.

Key Points: 
  • New York City is poised to launch the first congestion pricing plan to reduce traffic in a major U.S. metropolitan area.
  • Like many journeys in the Big Apple, this one has been punctuated by delays.
  • Once the system starts up, however, it’s expected to significantly reduce gridlock in Manhattan and generate billions of dollars to improve public transit citywide.
  • As an urban policy scholar, I’m looking forward to seeing New York’s plan go into effect.
  • But given the heavy costs that traffic imposes on public health and productivity, I’m encouraged to see a major U.S. city finally test this approach.

Nudging drivers

  • Congestion pricing is a response to externalities – costs or benefits that are generated by one party but incurred by another.
  • Clogged city streets and air pollution are externalities created by urban car users, many of whom live outside the city.
  • This approach is behind behavioral economics, the policy strategy of using “nudges” that preserve choice but encourage certain actions.

Public transit receives priority

  • The New York plan was presented to the board of the Metropolitan Transit Authority in November 2023 after years of study and a detailed environmental impact assessment, required by federal law.
  • It also would generate US$15 billion for capital improvements to the city’s public transit system, including making stations accessible for passengers with disabilities and buying new electric buses and commuter rail and subway cars.
  • More than 75% of all trips into the central business district are made by public transit.
  • Over several months of public hearings, the MTA heard both broad support for congestion pricing and thousands of requests for credits, discounts and exemptions, most of which were denied.
  • The limited number of exemptions includes private commuter buses, school buses and city-owned vehicles, including emergency vehicles.
  • New Jersey is suing the MTA, arguing among other things that the plan is unconstitutional because it burdens interstate commerce.

Starting the journey

  • And how will commuters respond when they find that trains and subways initially are more crowded, before capital upgrades improve the system?
  • But freedom for car users has imposed health and economic costs on millions of New Yorkers for many years.
  • But if New York’s experiment succeeds, it could provide a model and valuable insights for other traffic-clogged U.S. cities.


John Rennie Short does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Safer roads in Ireland with Connected Vehicles milestone

Retrieved on: 
Wednesday, April 10, 2024

Vienna/Dublin, March 19, 2024 – Ireland's NIMS (Network Intelligence and Management System) initiative is launching a C-ITS pilot project to increase traffic safety.

Key Points: 
  • Vienna/Dublin, March 19, 2024 – Ireland's NIMS (Network Intelligence and Management System) initiative is launching a C-ITS pilot project to increase traffic safety.
  • Since January 2024, C-ITS is fully integrated into the operational Traffic Management solution NIMS providing information to roadusers in realtime.
  • C-ITS allows the exchange of data between vehicles, infrastructure and authorities.
  • The NIMS project, of which Kapsch TrafficCom is a part since 2020, has a financial scope in the low double-digit million range.

Strong data from DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure

Retrieved on: 
Wednesday, April 3, 2024

The publication can be accessed here .

Key Points: 
  • The publication can be accessed here .
  • Dr. Jeffrey Testani, Associate professor at Yale University and senior author of the publication commented: “Cardiorenal syndrome is a major clinical challenge in heart failure with a clear unmet need for therapies to effectively and durably address congestion and cardio-renal dysfunction.
  • Currently the mainstay of therapy for sodium avidity and congestion are the loop diuretics, which actually worsen sodium avidity and cardiorenal syndrome.
  • Diuretic-resistant heart failure and cardiorneal syndrome are large and growing markets both in the US and rest of world, with the clear need for novel treatments that can improve clinical outcomes beyond loop diuretics.

AmpliTech Group’s Division AGTGSS, Riding The Crest Of Its Recent O-RAN CAT B 64T64R MIMO Radio Release, Teams Up With the Open6G OTIC at the Institute for the Wireless Internet of Things (WIoT) at Northeastern University To Perform O-RAN 5G Interoperabil

Retrieved on: 
Tuesday, April 2, 2024

The NU Open6G OTIC will provide a comprehensive platform for end-to-end and automated integration and testing of the AmpliTech O-RU in a multi-vendor environment.

Key Points: 
  • The NU Open6G OTIC will provide a comprehensive platform for end-to-end and automated integration and testing of the AmpliTech O-RU in a multi-vendor environment.
  • Several CU/DU (Central Unit/Distribution Unit) vendors have expressed interest in conducting interoperability testing with AGTGSS’s 64T64R O-RU.
  • Thanks to the Open6G OTIC support, new market entrants can gain an advantage and explore new solutions for O-RAN systems.
  • We are proudly teaming up with the Northeastern University Open6G OTIC to conduct this key interoperability testing and certification of our radios.

Sequana Medical announces 2023 Full Year Results and 2024 Outlook

Retrieved on: 
Thursday, March 28, 2024

Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: “Securing PMA approval is a major value inflection point and the team is navigating through the approval process.

Key Points: 
  • Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: “Securing PMA approval is a major value inflection point and the team is navigating through the approval process.
  • Furthermore, the alfapump can benefit from attractive pricing and leverage its FDA breakthrough device designation to enhance its reimbursement position.
  • Following this equity placement, the €3.0 million convertible loan agreement entered in February 2024 by Partners in Equity and Rosetta Capital will be mandatorily converted into new shares.
  • A day-100 meeting is scheduled with the FDA on April 9th 2024.

Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy

Retrieved on: 
Monday, March 25, 2024

These final data support DSR’s mechanism of action as breaking the vicious cycle of cardiorenal syndrome.

Key Points: 
  • These final data support DSR’s mechanism of action as breaking the vicious cycle of cardiorenal syndrome.
  • Unlike loop diuretics which, on average, have a negative impact on renal function and diuretic response, DSR has again demonstrated its potential to restore renal health and control of volume status.
  • Dramatic improvement in diuretic response and stable kidney function: During the four-week DSR treatment period, all three patients maintained euvolemia without the need of loop diuretics.
  • In January 2024, the independent DSMB approved the start of the randomized MOJAVE cohort following review of the safety data reported from the non-randomized cohort.

Japanese Investors Believe Increased Global Urbanisation is Set to Fuel Growth in eVTOL Sector

Retrieved on: 
Tuesday, March 19, 2024

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- New Horizon Aircraft Ltd. (NASDAQ: HOVR), doing business as Horizon Aircraft (“Horizon Aircraft” or the “Company”), a leading hybrid electric Vertical TakeOff and Landing (“eVTOL”) aircraft developer, publishes new global research* that indicates the global trend towards urbanisation is believed by Japanese private equity, venture capital and family office investors to be a key driver behind the anticipated growth in the eVTOL. The study from PureProfile, commissioned by the Company, surveyed investors in Japan responsible for more than $423 billion assets under management.

Key Points: 
  • The study from PureProfile, commissioned by the Company, surveyed investors in Japan responsible for more than $423 billion assets under management.
  • The need to address such transportation issues is believed by 65% of Japanese professional investors to be a key driver behind the growth of the eVTOL market.
  • Only 5% of professional investors in Japan believe the debut date for commercial passenger routes will extend beyond 2030.
  • Roughly three out of four (78%) Japanese investors believe public support for eVTOLs will grow over the next three years with 18% anticipating a dramatic increase in public confidence.

Majority of Ontarians disagree with Federal Minister’s statement that government should stop investing in new road infrastructure

Retrieved on: 
Thursday, March 14, 2024

“It is time for the federal government to accept the will of the people and support transformational infrastructure.

Key Points: 
  • “It is time for the federal government to accept the will of the people and support transformational infrastructure.
  • Today’s results show everyday people understand the critical need for these generational transportation infrastructure projects,” said Walid Abou-Hamde, CEO of ORBA.
  • The plan includes record investments in both road and transit infrastructure to support the country’s most populous and growing region, including support for housing and other required critical infrastructure.
  • www.rccao.com
    Background on ORBA: The Ontario Road Builders’ Association (ORBA) is the voice of the transportation infrastructure sector in Ontario.

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 13, 2024

BURLINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided a business update. 

Key Points: 
  • Product revenues were $6.1 million, and cost of product revenues were $1.8 million for the fourth quarter of 2023.
  • Research and development expenses were $3.3 million for the fourth quarter of 2023, compared to $2.3 million for the fourth quarter of 2022.
  • Selling, general and administrative expenses were $16.2 million for the fourth quarter of 2023, compared to $7.2 million for the fourth quarter of 2022.
  • scPharmaceuticals reported a net loss of $13.8 million for the fourth quarter of 2023, compared to $9.2 million for the fourth quarter of 2022.

Getaround Reports Full Year 2023 Results

Retrieved on: 
Thursday, March 28, 2024

Getaround (NYSE: GETR) (“Getaround'' or “the Company”), the world’s first connected carsharing marketplace, today announced financial results for the year ended December 31, 2023.

Key Points: 
  • Getaround (NYSE: GETR) (“Getaround'' or “the Company”), the world’s first connected carsharing marketplace, today announced financial results for the year ended December 31, 2023.
  • Subsequently, in February 2024 the board appointed Eduardo Iniguez as Chief Executive Officer and board member of Getaround.
  • “With proper leadership, adequate funding and thoughtful capital allocation, we should be able to scale the platform Getaround built over the past decade exponentially.
  • “In December 2022, we deployed a new version of our Getaround TrustScore to improve the trust and safety of our marketplace.